Similar articles

• Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.

  Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W. Mahaffey KW, et al. Ann Intern Med. 2013 Jun 18;158(12):861-8. doi: 10.7326/0003-4819-158-12-201306180-00003. Ann Intern Med. 2013. PMID: 23778903 Clinical Trial.
• An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

  Mantha S, Ansell J. Mantha S, et al. Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Thromb Haemost. 2012. PMID: 22740145 Review.
• End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.

  Mahaffey KW, Hellkamp AS, Patel MR, Hannan KL, Schwabe K, Nessel CC, Berkowitz SD, Halperin JL, Hankey GJ, Becker RC, Piccini JP, Breithardt G, Hacke W, Singer DE, Califf RM, Fox KA. Mahaffey KW, et al. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):470-8. doi: 10.1161/CIRCOUTCOMES.113.000132. Epub 2013 Jun 11. Circ Cardiovasc Qual Outcomes. 2013. PMID: 23759472 Clinical Trial.
• Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

  ROCKET AF Study Investigators. ROCKET AF Study Investigators. Am Heart J. 2010 Mar;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025. Am Heart J. 2010. PMID: 20211293 Clinical Trial.
• Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.

  Martínez-Rubio A, Dan GA, Kaski JC. Martínez-Rubio A, et al. Expert Rev Cardiovasc Ther. 2014 Aug;12(8):933-47. doi: 10.1586/14779072.2014.931223. Epub 2014 Jun 19. Expert Rev Cardiovasc Ther. 2014. PMID: 24948333 Review.